KPTI
Karyopharm Therapeutics Inc
NASDAQ: KPTI · HEALTHCARE · BIOTECHNOLOGY
$8.31
-1.07% today
Updated 2026-04-30
Market cap
$195.22M
P/E ratio
—
P/S ratio
1.34x
EPS (TTM)
$-17.80
Dividend yield
—
52W range
$4 – $11
Volume
1.0M
Karyopharm Therapeutics Inc (KPTI) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $152000.00 | $634000.00 | $387000.00 | $229000.00 | $250000.00 | $154000.00 | $1.60M | $30.34M | $40.89M | $108.08M | $209.82M | $157.07M | $146.03M | $145.24M | $146.07M |
| Revenue growth (YoY) | — | +317.1% | -39.0% | -40.8% | +9.2% | -38.4% | +942.2% | +1790.1% | +34.8% | +164.3% | +94.1% | -25.1% | -7.0% | -0.5% | +0.6% |
| Cost of revenue | $10.38M | $14.10M | $34.19M | $60.13M | $97.74M | $86.94M | $107.27M | $161.37M | $2.41M | $2.71M | $3.40M | $5.21M | $4.94M | $6.01M | $5.95M |
| Gross profit | $152000.00 | $-13.46M | $387000.00 | $-59.90M | $250000.00 | $154000.00 | $1.60M | $-131.04M | $38.49M | $105.38M | $206.42M | $151.86M | $141.09M | $139.23M | $140.12M |
| Gross margin | 100.0% | -2123.2% | 100.0% | -26156.3% | 100.0% | 100.0% | 100.0% | -431.9% | 94.1% | 97.5% | 98.4% | 96.7% | 96.6% | 95.9% | 95.9% |
| R&D | $8.62M | $14.10M | $28.45M | $60.13M | $97.74M | $86.94M | $107.27M | $161.37M | $122.34M | $150.81M | $160.84M | $148.66M | $138.75M | $143.23M | $125.62M |
| SG&A | $1.84M | $2.43M | $5.88M | $15.95M | $21.58M | $23.95M | $24.87M | $48.85M | $105.42M | $126.42M | $143.85M | $145.40M | $131.88M | $115.44M | $105.21M |
| Operating income | $-10.31M | $-15.89M | $-33.95M | $-75.85M | $-119.08M | $-110.73M | $-130.54M | $-179.88M | $-189.28M | $-171.85M | $-98.27M | $-142.20M | $-129.54M | $-119.44M | $-90.71M |
| Operating margin | -6783.6% | -2506.3% | -8772.6% | -33120.5% | -47630.4% | -71903.9% | -8133.2% | -593.0% | -462.9% | -159.0% | -46.8% | -90.5% | -88.7% | -82.2% | -62.1% |
| EBITDA | $-10.23M | $-15.77M | $-33.81M | $-75.45M | $-118.44M | $-110.02M | $-129.82M | $-175.15M | $-182.93M | $-167.85M | $-96.98M | $-139.31M | $-118.42M | $-38.60M | $-90.41M |
| EBITDA margin | -6728.9% | -2486.8% | -8735.4% | -32949.3% | -47376.8% | -71438.3% | -8088.8% | -577.4% | -447.3% | -155.3% | -46.2% | -88.7% | -81.1% | -26.6% | -61.9% |
| EBIT | $-10.31M | $-15.89M | $-33.95M | $-75.78M | $-119.08M | $-110.73M | $-130.54M | $-175.89M | $-183.90M | $-168.82M | $-97.77M | $-139.93M | $-118.95M | $-38.94M | $-90.71M |
| Interest expense | $0.00 | $2000.00 | $3000.00 | $1000.00 | $895000.00 | $1.29M | $1.62M | $2.49M | $15.65M | $27.14M | $26.05M | $25.00M | $23.82M | $37.42M | $45.85M |
| Income tax | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-10.31M | $-15.89M | $-33.95M | $-75.78M | $-118.18M | $-109.58M | $-128.98M | $-178.41M | $-199.59M | $-196.27M | $-124.09M | $-165.29M | $-143.10M | $-76.42M | $-196.04M |
| Net income growth (YoY) | — | -54.1% | -113.7% | -123.2% | -56.0% | +7.3% | -17.7% | -38.3% | -11.9% | +1.7% | +36.8% | -33.2% | +13.4% | +46.6% | -156.5% |
| Profit margin | -6783.6% | -2506.0% | -8771.8% | -33090.4% | -47272.4% | -71153.9% | -8036.4% | -588.1% | -488.1% | -181.6% | -59.1% | -105.2% | -98.0% | -52.6% | -134.2% |